RBRX.F Stock Overview
Rhino Biotech Limited intends to develop plant and fungi derived nutraceuticals, and preventative and curative biopharmaceuticals. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Rhino Biotech Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.0001 |
52 Week High | US$0.0001 |
52 Week Low | US$0.000001 |
Beta | 0 |
11 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
33 Year Change | -99.17% |
5 Year Change | -97.78% |
Change since IPO | -98.00% |
Recent News & Updates
Recent updates
Shareholder Returns
RBRX.F | US Oil and Gas | US Market | |
---|---|---|---|
7D | 0% | -1.4% | 1.0% |
1Y | n/a | 15.5% | 31.4% |
Return vs Industry: Insufficient data to determine how RBRX.F performed against the US Oil and Gas industry.
Return vs Market: Insufficient data to determine how RBRX.F performed against the US Market.
Price Volatility
RBRX.F volatility | |
---|---|
RBRX.F Average Weekly Movement | n/a |
Oil and Gas Industry Average Movement | 5.6% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 16.3% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RBRX.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine RBRX.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | n/a | Nick Baxter | ir.rhinobiotech.com |
Rhino Biotech Limited intends to develop plant and fungi derived nutraceuticals, and preventative and curative biopharmaceuticals. The company was formerly known as Eurasia Energy Limited and changed its name to Rhino Biotech Limited in September 2021. Rhino Biotech Limited was incorporated in 2003 and is based in South Hill, Anguilla.
Rhino Biotech Limited Fundamentals Summary
RBRX.F fundamental statistics | |
---|---|
Market cap | US$3.10k |
Earnings (TTM) | -US$21.23k |
Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs RBRX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RBRX.F income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$21.23k |
Earnings | -US$21.23k |
Last Reported Earnings
Dec 31, 2020
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did RBRX.F perform over the long term?
See historical performance and comparison